The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Open accessAbstract
BACKGROUND: Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. METHODS: In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab. The primary end point was overall survival, assessed among all patients who underwent randomization (overall population) and among those with tumors positive for programmed cell death ligand 1 (PD-L1). Secondary end points included progression-free survival and safety. RESULTS: Among all 700 patients who underwent randomization, the addition of maintenance avelumab to best supportive care significantly prolonged overall survival as compared with best supportive care alone (control). Overall survival at 1 year was 71.3% in the avelumab group and 58.4% in the control group (median overall survival, 21.4 months vs. 14.3 months; hazard ratio for death, 0.69; 95% confidence interval [CI], 0.56 to 0.86; P = 0.001). Avelumab also significantly prolonged overall survival in the PD-L1-positive population; overall survival at 1 year was 79.1% in the avelumab group and 60.4% in the control group (hazard ratio, 0.56; 95% CI, 0.40 to 0.79; P<0.001). The median progression-free survival was 3.7 months in the avelumab group and 2.0 months in the control group in the overall population (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75) and 5.7 months and 2.1 months, respectively, in the PD-L1-positive population (hazard ratio, 0.56; 95% CI, 0.43 to 0.73). The incidence of adverse events from any cause was 98.0% in the avelumab group and 77.7% in the control group; the incidence of adverse events of grade 3 or higher was 47.4% and 25.2%, respectively. CONCLUSIONS: Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number, NCT02603432.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Self-citationRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Self-citationvon der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Self-citationvon der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Self-citationBalar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
Self-citationPowles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Self-citationGalsky, M. D., Arija, J. Á. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., Garcia-del-Muro, X., De Giorgi, U., Mencinger, M., Izumi, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30230-0 · Cited by 786
Self-citationDe Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Self-citationSharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz127 · Cited by 480
Self-citationDogliotti, L., Cartenì, G., Siena, S., Bertetto, O., Martoni, A., Bono, A., Amadori, D., Onat, H., & Marini, L. (2007) · European Urology · doi:10.1016/j.eururo.2006.12.029 · Cited by 330
Powles, T., Huddart, R. A., Elliott, T., Sarker, S.-J., Ackerman, C., Jones, R., Hussain, S., Crabb, S., Jagdev, S., Chester, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.3468 · Cited by 206
Self-citationPD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s135157 · Cited by 144
Galsky, M. D., Mortazavi, A., Milowsky, M. I., George, S., Gupta, S. V., Fleming, M. T., Dang, L. H., Geynisman, D. M., Walling, R., Alter, R. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03091 · Cited by 144
Self-citationThe Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
van Dijk, N., Funt, S. A., Blank, C. U., Powles, T. B., Rosenberg, J. E., & van der Heijden, M. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.022 · Cited by 125
Self-citationResponse Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
Szabados, B. E., van Dijk, N., Tang, Y. Z., van der Heijden, M. S., Wimalasingham, A. G., de Liaño, A. G., Chowdhury, S., Hughes, S. R., Rudman, S. M., Linch, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.022 · Cited by 121
Self-citationEckstein, M., Erben, P., KRIEGMAIR, M. C., Worst, T. S., Weiss, C. A., Wirtz, R. M., Wach, S., Stoehr, R., Sikic, D., Geppert, C. I., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.007 · Cited by 110
Grivas, P. D., Daignault, S. D., Tagawa, S. T., Nanus, D. M., Stadler, W. M., Dreicer, R., Kohli, M., Petrylak, D. P., Vaughn, D. J., Bylow, K. A., et al. (2013) · Cancer · doi:10.1002/cncr.28477 · Cited by 98
Self-citationImmune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Gopalakrishnan, D., Koshkin, V. S., Ornstein, M. C., Papatsoris, A., & Grivas, P. D. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158753 · Cited by 65
Self-citationGrivas, P. D., Monk, B. J., Petrylak, D. P., Reck, M., Foley, G., Guenther, S., Hennessy, D., Makris, C., & Moehler, M. H. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00665-1 · Cited by 61
Self-citationSchwamborn, K., Ammann, J. U., Knüchel, R., Hartmann, A., Baretton, G. B., Lasitschka, F., Schirmacher, P., Braunschweig, T. A., Tauber, R., Erlmeier, F., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02610-z · Cited by 60
Zajac, M., Scott, M. L. J., Ratcliffe, M., Scorer, P., Barker, C., Al‐Masri, H., Rebelatto, M. C., & Walker, J. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0873-6 · Cited by 51
García-Donás, J., Pous, A. F., Pérez‐Valderrama, B., Virizuela, J. A., Climent, M. Á., Polo, S. H., Arranz, J. Á., Llorente, M. D. M., Laínez, N., Villa-Guzmán, J. C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30242-5 · Cited by 50
Update on the Treatment of Metastatic Urothelial Carcinoma
Bukhari, N., Al-Shamsi, H. O., & Azam, F. (2018) · The Scientific World JOURNAL · doi:10.1155/2018/5682078 · Cited by 50
Sonpavde, G., Mariani, L., Vullo, S. L., Raggi, D., Giannatempo, P., Bamias, A., Crabb, S. J., Joaquim Bellmunt, B., Yu, E. Y., Niegisch, G., et al. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.07.035 · Cited by 47
Self-citationEmerging immunotherapies for bladder cancer
Kim, J. W., Tomita, Y., Trepel, J. B., & Apolo, A. B. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000177 · Cited by 35
Zajac, M., Boothman, A.-M., Ben, Y., Gupta, A. K., Jin, X., Mistry, A., Sabalos, C. M., Nielsen, A., Manriquez, G., Barker, C., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0555-oa · Cited by 33
Apolo, A. B., Ellerton, J. A., Infante, J. R., Agrawal, M., Gordon, M. S., Aljumaily, R. M., Britten, C. D., Dirix, L. Y., Lee, K., Taylor, M. H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.425 · Cited by 8
Cited by
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Self-citationEnfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Powles, T., Valderrama, B. P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Park, S. H., Shin, S. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312117 · Cited by 1,103
Self-citationHuang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
“Chemotherapy followed by avelumab Locally advanced or metastatic urothelial carcinoma June 30, 2020 [58]”
Background
Metadata
- Authors
- Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., Loriot, Y., Sridhar, S. S., Tsuchiya, N., Kopyltsov, E., Sternberg, C. N., Bellmunt, J., Aragon-Ching, J. B., Petrylak, D. P., Laliberte, R., Wang, J., Huang, B., Davis, C., Fowst, C., Costa, N., Blake-Haskins, J. A., di Pietro, A., & Grivas, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-09-24
- Volume
- 383
- Issue
- 13
- Pages
- 1218-1230
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3087464965
- Cited by
- 1,493
- References
- 35
- FWCI
- 171.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.